Dr. Ian Flinn

“We now have second and third generation cousins of thalidomide that are very useful. So, lenalidomide in combination with rituximab is an effective therapy for mantle cell lymphoma that voids some of these adverse events that I’m talking about,” said Dr. Ian Flinn. Hear more about this treatment in his interview with CURE®.

“I think we’re in a midst of a real shakeup in our treatment paradigms for patients with mantle cell lymphoma, or at least we will be in the next few years,” said Dr. Ian Flinn in an interview with CURE®.

The development of bispecific antibodies and antibody drug conjugates could be exciting advancements for patients with lymphomas, including mantle cell lymphoma, according to Dr. Ian Flinn.

Evidence shows that Bruton’s tyrosine kinase inhibitors, one of many targeted therapies, are highly effective in patients with mantle cell lymphoma.

The evolution of CAR T-cell therapy has been an exciting development for the treatment of all lymphomas, including mantle cell lymphoma, according to Dr. Ian Flinn.